Advancing Cxbladder as standard of care - Clinical Study
Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces it is advancing its clinical evidence generation program with LOBSTER (Longitudinal Bladder Cancer Study for Tumor Recurrence) – a multi-centre observational clinical study focused on demonstrating the clinical utility of Cxbladder Monitor for surveillance of recurrent urothelial cancer against the current American Urological Association (AUA) standard of care targeting existing guidelines language for greater inclusion of Cxbladder.
Pacific Edge has contracted two sites, has initiated one site to date, and expects to enrol the first patient in LOBSTER this quarter.
See attachment for full press release.
Markets News
Bear markets can be stressful but they also present opportunities for investors, says Salt Funds' Greg Fleming.
Peter McIntyre, an investment adviser at Craigs Investment Partners, said it had been a “strong performance” in today’s market.
The head of the multinational logistics group says having container cranes sitting idle across the country is a waste of assets
The zero-brokerage fee share trading platform is looking for ways to bring in revenue and make its business model more sustainable.
Fletcher Building achieved second-half profit margins of 9.5%, just below its target of 10% by the 2023 financial year.
Eroad had a second day as the index’s biggest decliner, falling more than 5% to $1.57 and bringing its decline over the past year to almost 75%.
Fletcher's new plant at Tauriko, due to open next year, will increase industry capacity by 30%.
Even under a “bear-case scenario”, the house building pipeline should support Fletcher’s medium-to-long-term performance.
Some investors in NZ’s market took the opportunity to buy up “beaten up” stock on the index today, Devon Funds' Greg Smith said.
Trading volumes were unusually light, with US markets closed tonight for a national holiday.
The shareholder representatives say the Fletcher board must bear ultimate responsibility for the company’s poor performance and the Gib plasterboard shortage.
NZME has only spent $5.3m of the $30m set aside for share buybacks.
Are banks being too slow to raise term deposit rates? Some analysts say yes.
Peter McIntyre, an investment adviser at Craigs Investment Partners, says New Zealand’s market has been "reliably well-behaved over the course of the day".
The firm has doubled its headcount and is looking to raise capital to expand its manufacturing and engineering focus into green hydrogen applications.
Meridian says the fact that Australia's electricity market has turned into a train wreck shows its decision to pull out was the right one.
The Ministry for Primary Industries estimated Fonterra’s restructuring would cost the average farmer between $135,000 and $400,000.
New Zealand's biggest transport operator plans to have its first 10 dual-fuel hydrogen trucks on the road next year.
Oanda market analyst Edward Moya said the absence of a Bitcoin rally could be a troubling sign for some investors.
Sky TV and MediaWorks will be brushing themselves off after a bruising response to their proposal scotched a SkyWorks deal.
Sky TV has backed away from a dalliance with radio and outdoor advertising.
An annual survey of investor confidence shows the market fall has got some people rattled.
It's important that constraints remain on Fonterra that counterbalance its privileged position in the dairy sector and the national economy, says TDB Advisory.
BNZ Research said there was now “a good chance” the Reserve Bank of NZ would hike 75 basis points when it meets next month.